Effect of Different Dosages of Rosuvastatin on Patients with Acute Cerebral Infarction
Objective To investigate the effect of rosuvastatin at different dosages on acute cerebral infarction(ACI).Methods A retrospective analysis was conducted on 60 patients with ACI admitted to The First People's Hospital of Zhengzhou City from January 2019 to June 2023.The patients were divided into two groups based on different medication regimens.The study group(n=30)received 20 mg of rosuvastatin,while the control group(n=30)received 10 mg of rosuvastatin.The therapeutic effects,degree of neurological functional impairment,activities of daily living(ADL-Barthel),inflammatory factors[interleukin-6(IL-6),high-sensitivity C-reactive protein(hs-CRP),tumor necrosis factor-alpha(TNF-α)],matrix metalloproteinase-9(MMP-9),and plasma placental growth factor(PLGF)levels were compared between the two groups.Results The effective rate of treatment in the study group was higher than that in the control group,with statistically significant differences(P＜0.05).There were no statistically significant differences in the National Institutes of Health Stroke Scale(NIHSS)and ADL-Barthel scores between the two groups before treatment(P＞0.05).However,after 6 and 12 weeks of treatment,the ADL-Barthel score was higher and the NIHSS score was lower in the study group compared to the control group,with statistically significant differences(P＜0.05).There were no statistically significant differences in the levels of inflammatory factors between the two groups before treatment(P＞0.05).However,after 6 and 12 weeks of treatment,the levels of IL-6,TNF-α,and hs-CRP decreased in both groups,with the levels being lower in the study group compared to the control group,with statistically significant differences(P＜0.05).There were no statistically significant differences in MMP-9 and PLGF levels between the two groups before treatment(P＞0.05).However,after 6 and 12 weeks of treatment,the levels of MMP-9 and PLGF decreased in both groups,with the levels being lower in the study group compared to the control group,with statistically significant differences(P＜0.05).Conclusion In patients with ACI,the combination of a higher dose of rosuvastatin with routine symptomatic treatment can improve neurological function,MMP-9,and PLGF levels,and enhance the quality of daily life,which is worthy of clinical reference.
acute cerebral infarctionrosuvastatinneurological function
国家科技期刊平台
NSTL
万方数据
